Haifaa Abdulhaq

6PUBLICATIONS
25CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)AutoimmunityMedical mycologyHaematological tumoursMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 10, 2026
Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

|Nov 12, 2025
Heterogeneous Presentations of iMCD: A Single-Institution Case Series.

Jaspreet Kaur, Anthony Sisk, Jonathan E Zuckerman

|Nov 16, 2023
Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study.

Fredrik H Schjesvold, Heinz Ludwig, Maria-Victoria Mateos

|Jul 26, 2023
Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context.

Haifaa Abdulhaq, Andrew Hwang, Omar Mahmood

|Jul 07, 2022
Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham's Lymphangiomatosis: Review of the Literature.

Matthew Lee, Beth A Martin, Haifaa Abdulhaq

|Jan 11, 2021
Efficacy of Venetoclax and Dexamethasone in Refractory IgM Primary Plasma Cell Leukemia with t(11;14) and TP53 Mutation: A Case Report and Literature Review.

Salimah Valliani, Mir Ali, Omar Mahmoo

Pageof 1

Frequent Collaborators

1 joint publications

Salimah Valliani

1 joint publications

Mir Ali

1 joint publications

Omar Mahmoo

1 joint publications

Sanjay Hinduja